Lyell Immunopharma (LYEL) Stock Forecast
AI forecast: LYEL
There is no current AI forecast for this stock.
The AI publishes a target price for the next trading day, the end of the week and the end of the month. The change is measured from the latest price. These are statistical estimates, not investment advice.
Premium shows the AI's price targets for 1 day, 1 week and 1 month for this and every other stock.
Unlock PremiumAbout This Company
Lyell Immunopharma specializes in cell therapy, focusing on the reprogramming of T-lymphocytes for the treatment of solid tumors. The company’s technologies are applicable regardless of biological targets and their associated pathways, and are utilized in chimeric antigen receptor (CAR) T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and T-cell receptor (TCR) therapy. Lyell Immunopharma is currently developing a pipeline of products designed to deliver comprehensive therapeutic effects across various forms of solid tumors that are difficult to treat.
